Muckle-Wells Syndrome (MWS) Cell Models for Research

Muckle-Wells Syndrome (MWS) is a rare autoinflammatory disease with an estimated prevalence of 1 in 1,000,000. It is one of the cryopyrin-associated periodic syndromes (CAPS) caused by gain-of-function mutations in the NLRP3 gene. Clinically, MWS presents with recurrent fever, urticarial rash, arthralgia, and progressive sensorineural hearing loss. If untreated, it can lead to amyloidosis and renal failure. The disease significantly impacts quality of life and requires lifelong management. Early diagnosis and treatment with IL-1 inhibitors have improved outcomes, but many patients still experience complications. Research into MWS is crucial for understanding inflammasome biology and developing targeted therapies.

MWS serves as an excellent model for studying the NLRP3 inflammasome, a key component of innate immunity. The disease is monogenic, making it amenable to genetic manipulation. Public datasets, such as those from ClinVar and the Infevers registry, provide mutation information. Open questions include the precise molecular mechanisms of NLRP3 activation, the role of specific mutations in disease severity, and the development of resistance to IL-1 inhibitors. Gene-edited cell models enable functional studies of these mutations in a controlled environment.

The central pathway in MWS is the NLRP3 inflammasome pathway. Steps include:

1. Priming: NF-κB activation upregulates NLRP3 and pro-IL-1β expression.

2. Activation: Mutated NLRP3 leads to constitutive or hyperactive inflammasome assembly.

3. Caspase-1 activation: Cleaves pro-IL-1β and pro-IL-18 into active cytokines.

4. Pyroptosis: Gasdermin D cleavage triggers inflammatory cell death.

Additionally, the NF-κB pathway is involved in priming, and the MAPK pathway may modulate cytokine production.

Data from ClinVar and Infevers. Most mutations cluster in the NACHT domain.

Key networks include:

• • NLRP3 inflammasome: NLRP3, ASC, Caspase-1, IL-1β, IL-18.
• • NF-κB signaling: TLRs, MyD88, IRAK, TRAF6, IKK complex.
• • MAPK pathway: ERK, JNK, p38.
• • Cytokine signaling: IL-1 receptor, IL-18 receptor.

These networks are interconnected; NLRP3 activation leads to cytokine release, which further amplifies inflammation.

Organoids derived from patient iPSCs are emerging as more physiologically relevant models, allowing study of tissue-specific effects.

Animal models for MWS include:

• • GEMM (Genetically Engineered Mouse Models): Mice carrying NLRP3 mutations (e.g., A350V) recapitulate MWS symptoms.
• • Induced models: Injection of uric acid crystals to activate NLRP3.
• • PDX (Patient-Derived Xenografts): Not commonly used for MWS due to the immune nature, but humanized mice can be used.

These models are valuable for studying systemic inflammation and testing therapies.

CRISPR-based gene editing allows the creation of isogenic cell lines with specific NLRP3 mutations. For example:

• • NLRP3 knockout cell lines: Loss-of-function to study inflammasome inhibition.
• • NLRP3 knock-in cell lines: Introduction of disease-associated mutations (e.g., A439V) to model hyperactivation.
• • Reporter cell lines: IL-1β promoter-driven reporters to monitor pathway activation.

These models are commercially available, sequence-verified, and provide a controlled system for drug screening and mechanistic studies.

Gene-edited cells are used to validate the role of NLRP3 mutations in disease. For example, knocking in a specific mutation into a wild-type cell line can confer hyperactive inflammasome activity, confirming causality. Conversely, knocking out NLRP3 in patient-derived cells can rescue the phenotype. These models enable high-throughput screening for genetic modifiers.

Isogenic pairs (wild-type vs. mutant) are ideal for drug screening. They allow identification of compounds that specifically inhibit mutant NLRP3. Additionally, they can be used to study resistance mechanisms to IL-1 inhibitors by exposing cells to increasing drug concentrations and selecting resistant clones.

CRISPR screens using gene-edited cells can identify synthetic lethal partners of NLRP3 mutations. For instance, knocking out genes in a mutant background can reveal vulnerabilities that could be targeted therapeutically. This approach may lead to novel biomarkers for patient stratification.